Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-RiskAssessment

More Like This

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

PR Newswire associated0

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

ACCESSWIRE associated1

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling

ACCESSWIRE logo

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

PR Newswire associated0

Pioneering the Next Frontier: ArisGlobal Unveils Cutting-Edge Safety & Regulatory Product Offerings Powered by Generative AI